Data Foundry

Drug recalls 2023

buPROPion Hydrochloride Extended-Release Tablets — Class III drug recall D-0137-2024

Terminated recall by SUN PHARMACEUTICAL INDUSTRIES INC, reported 2023-12-13, distributed nationwide. Failed Dissolution Specifications

Recall numberD-0137-2024
Product typeDrug
ClassificationClass III
StatusTerminated
Voluntary or mandatedVoluntary
Recalling firmSUN PHARMACEUTICAL INDUSTRIES INC, Princeton, NJ, United States
Recall initiated2023-11-22
Classified2023-12-01
Reported by FDA2023-12-13
Terminated2024-06-27
DistributedNationwide (US)
Quantity2,016 bottles
Reason classesspecification failure
NDC47335-0736, 47335-0736-08, 47335-0736-13, 47335-0736-86, 47335-0736-88, 47335-0737, 47335-0737-08, 47335-0737-13, 47335-0737-86, 47335-0737-88, 47335-0738, 47335-0738-08, 47335-0738-13, 47335-0738-86, 47335-0738-88
Lot numbersHAD0630A
Expiration dates2024-01

Product

buPROPion Hydrochloride Extended-Release Tablets, USP (SR) 200 mg, 60 Tablets bottle, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited, Halol-Baroda Highway, Halol-389 350, Gujarat, India NDC 47335-738-86

Reason for recall

Failed Dissolution Specifications

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0137-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.